PRESS RELEASE published on 01/26/2024 at 14:00, 2 years 7 months ago Optimind Pharma - Debenture Conversion Optimind Pharma Corp. (CSE:OMND) announces agreement to convert $303,750 convertible debentures at $0.025/share, potentially issuing 23,333,500 shares. Optimind focuses on psychedelic therapies for mental health. Convertible Debentures Optimind Pharma Corp. CSE:OMND Psychedelic Therapies Mental Health
PRESS RELEASE published on 12/19/2023 at 13:30, 2 years 8 months ago Optimind Pharma Provides Corporate Update
Published on 09/12/2026 at 02:35, 2 days 2 hours ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 2 days 6 hours ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 21:25, 2 days 8 hours ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 2 days 12 hours ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/14/2026 at 04:40, 54 minutes ago ZPMC Showcases Offshore Engineering Capabilities at SMM 2026 in Hamburg
Published on 09/14/2026 at 02:05, 3 hours 29 minutes ago Shanghai Electric Secures First Overseas Heavy-Duty Gas Turbine Order for 500 MW Malaysian Project
Published on 09/13/2026 at 16:45, 12 hours 49 minutes ago Journées européennes du patrimoine : un succès populaire pour l'ouverture exceptionnelle du Siège de la Vaudoise
Published on 09/12/2026 at 17:50, 1 day 11 hours ago New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Published on 09/12/2026 at 07:30, 1 day 22 hours ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 07:00, 2 days 22 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 2 days 22 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 3 days 10 hours ago Availability of the 2026 Interim Financial Report
